Pale Yellow Crystalline Solid
Αn α-adrenergic antagonist. A peripheral vasodilator.
a-adrenergic antagonist. A peripheral vasodilator
ChEBI: Tolazoline hydrochloride is a member of benzenes.
The phenyl-acetiminoether hydrochloride of the formula
from 12 parts of benzylcyanide and ethanol and HCl is mixed with 8 parts of
ethylenediamine hydrate which has been diluted with little alcohol, whereby
the crystals go into solution. The whole is then heated on the water-bath until
the ammonia odor has disappeared, cooled, concentrated caustic potash
solution added, and the separated oil extracted with ether. The solution is
dried with potassium carbonate and potassium hydroxide. After evaporation a
pale oil is left which distills at 147°C under a pressure of 9 mm and which
solidifies in the condenser to a white crystalline mass. The yield amounts to
90% of the theory. The hydrochloride melts at 168° to 170°C.
Tolazoline is INN and
BAN.
Poison by ingestion,
intravenous, and intraperitoneal routes.
Human systemic effects by intravenous
route: change in heart rate, sweating,
ulceration or bleeding from duodeum,
ulceration or bleeding from small intestine,
unspecified vascular effects. When heated to
decomposition it emits very toxic fumes of
NO, and HCl.
Veterinary Drugs and Treatments
flipping of lips); piloerection;
clear lacrimal & nasal discharge; muscle fasciculations;
apprehensiveness
Uses/Indications
Tolazoline is approved and indicated for the reversal of effects associated
with xylazine in horses. It has also been used for this purpose
in a variety of other species as well, but less safety and efficacy data
is available.
In humans, the primary uses for tolazoline are: treatment of persistent
pulmonary hypertension in newborns, adjunctive treatment
and diagnosis
